These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation. Duhamel P; Suberbielle C; Grimbert P; Leclerc T; Jacquelinet C; Audry B; Bargues L; Charron D; Bey E; Lantieri L; Hivelin M Transpl Int; 2015 May; 28(5):582-93. PubMed ID: 25683513 [TBL] [Abstract][Full Text] [Related]
3. Screening of HLA sensitization during acute burn care. Klein HJ; Lehner F; Schweizer R; Rüsi-Elsener B; Nilsson J; Plock JA Burns; 2018 Aug; 44(5):1330-1335. PubMed ID: 29929900 [TBL] [Abstract][Full Text] [Related]
4. Sensitization and desensitization of burn patients as potential candidates for vascularized composite allotransplantation. Klein HJ; Schanz U; Hivelin M; Waldner M; Koljonen V; Guggenheim M; Giovanoli P; Gorantla VS; Fehr T; Plock JA Burns; 2016 Mar; 42(2):246-57. PubMed ID: 26392022 [TBL] [Abstract][Full Text] [Related]
5. Sensitization and Desensitization in Vascularized Composite Allotransplantation. Moris D; Cendales LC Front Immunol; 2021; 12():682180. PubMed ID: 34456906 [TBL] [Abstract][Full Text] [Related]
6. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. Wang HD; Fidder SAJ; Miller DT; Furtmüller GJ; Ahmadi AR; Nägele F; Lopez J; Quan A; Budihardjo J; Lough DM; Akpinarli B; Etra JW; Vasilic D; Raimondi G; Lee WPA; Montgomery RA; Sun Z; Brandacher G Transplantation; 2018 Apr; 102(4):593-600. PubMed ID: 29298238 [TBL] [Abstract][Full Text] [Related]
7. Immunological Effect of Skin Allograft in Burn Treatment: Impact on Future Vascularized Composite Allotransplantation. Garza RM; Press BH; Tyan DB; Karanas YL; Lee GK J Burn Care Res; 2017; 38(3):169-173. PubMed ID: 27801681 [TBL] [Abstract][Full Text] [Related]
9. Pre-transplant management and sensitisation in vascularised composite allotransplantation: A systematic review. Geoghegan L; Al-Khalil M; Scarborough A; Murray A; Issa F J Plast Reconstr Aesthet Surg; 2020 Sep; 73(9):1593-1603. PubMed ID: 32475735 [TBL] [Abstract][Full Text] [Related]
10. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period. Sánchez-Zapardiel E; Castro-Panete MJ; Castillo-Rama M; Morales P; Lora-Pablos D; Valero-Hervás D; Ruiz-García R; Apaza J; Talayero P; Andrés A; Morales JM; Paz-Artal E Transplantation; 2013 Jul; 96(1):70-8. PubMed ID: 23624543 [TBL] [Abstract][Full Text] [Related]
11. Graft vasculopathy of vascularized composite allografts in humans: a literature review and retrospective study. Ng ZY; Lellouch AG; Rosales IA; Geoghegan L; Gama AR; Colvin RB; Lantieri LA; Randolph MA; Cetrulo CL Transpl Int; 2019 Aug; 32(8):831-838. PubMed ID: 30829423 [TBL] [Abstract][Full Text] [Related]
12. Donor-specific antibodies and antibody-mediated rejection in vascularized composite allotransplantation. Weissenbacher A; Loupy A; Chandraker A; Schneeberger S Curr Opin Organ Transplant; 2016 Oct; 21(5):510-5. PubMed ID: 27517505 [TBL] [Abstract][Full Text] [Related]
13. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients. Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243 [TBL] [Abstract][Full Text] [Related]
14. Immunological and inflammatory mapping of vascularized composite allograft rejection processes in a rat model. Friedman O; Carmel N; Sela M; Abu Jabal A; Inbal A; Ben Hamou M; Krelin Y; Gur E; Shani N PLoS One; 2017; 12(7):e0181507. PubMed ID: 28746417 [TBL] [Abstract][Full Text] [Related]
15. A novel rat full-thickness hemi-abdominal wall/hindlimb osteomyocutaneous combined flap: influence of allograft mass and vascularized bone marrow content on vascularized composite allograft survival. Ramirez AE; Cheng HY; Lao WW; Wang YL; Wen CJ; Wallace CG; Lin CF; Shih LY; Chuang SH; Wei FC Transpl Int; 2014 Sep; 27(9):977-86. PubMed ID: 24861714 [TBL] [Abstract][Full Text] [Related]
16. Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Kueckelhaus M; Fischer S; Seyda M; Bueno EM; Aycart MA; Alhefzi M; ElKhal A; Pomahac B; Tullius SG Transpl Int; 2016 Jun; 29(6):655-62. PubMed ID: 26265179 [TBL] [Abstract][Full Text] [Related]
17. De novo donor-specific HLA antibodies after combined intestinal and vascularized composite allotransplantation - a retrospective study. Weissenbacher A; Vrakas G; Chen M; Reddy S; Allan P; Giele H; Barnardo MCNM; Vaidya A; Friend PJ; Fuggle SV Transpl Int; 2018 Apr; 31(4):398-407. PubMed ID: 29150964 [TBL] [Abstract][Full Text] [Related]
18. Vascularized Composite Allotransplantation in Burn Reconstruction: Systematic Review and Meta-analysis. Gray KM; Peterson JM; Padilla PL; Smith JM; Zapata-Sirvent RL; Branski LK; Norbury WB; Dziewulski P J Burn Care Res; 2021 May; 42(3):465-472. PubMed ID: 33091131 [TBL] [Abstract][Full Text] [Related]
19. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]